Aspects of fetal thyroid dose following iodine-131 administration during early stages of pregnancy in patients suffering from benign thyroid disorders

European Journal of Nuclear Medicine

Volumn 26, Issue 11, 1999, Pages 1453-1457

  Pauwels, E K J ^a   Thomson, W H ^b   Blokland, J A K ^a   Schmidt, M E ^a   Bourguignon, M ^c,d   El Maghraby, T A F ^a   Broerse, J J ^a   Harding, L K ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CITY HOSPITAL   (United Kingdom)

^c Off Protect Contre Rayon I   (France)

^d SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

Fetal thyroid; Fetus; Iodine 131; Prenatal irradiation; Radiation dose

Indexed keywords

IODINE 131; RADIOPHARMACEUTICAL AGENT;

ARTICLE; FEMALE; FETUS; FETUS DISEASE; FIRST TRIMESTER PREGNANCY; HUMAN; RADIATION DOSE; THYROID DISEASE; THYROTOXICOSIS;

ABNORMALITIES, RADIATION-INDUCED; ANIMALS; FEMALE; FETUS; HUMANS; IODINE RADIOISOTOPES; PREGNANCY; PREGNANCY COMPLICATIONS; RADIATION DOSAGE; RADIATION PROTECTION; RADIOMETRY; THYROID DISEASES; THYROID GLAND;

EID: 0032743309     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050478     Document Type: Article

References (28)

1. Mole RH. The biology and radiobiology of in utero development in relation to radiological protection. Br J Radiol 1993; 66: 1095-102.
2. Dekaban AS. Abnormalities in children exposed to x-radiation during various stages of gestation: tentative timetable of radiation to the human fetus:1. J Nucl Med 1968; 9: 471-477.
3. Steenvoorde P, Pauwels EKJ, Harding KL, Bourguignon M, Mazière B, Broerse JJ. Diagnostic nuclear medicine and risk for the fetus. Eur J Nucl Med 1998; 25: 193-199.
4. Jablon S, Kato H. Childhood cancer in relation to prenatal exposure to atomic-bomb radiation. Lancet 1970; II: 1000-1003.
5. Ennis J, Muirhead CR. X-rays in pregnancy and risk of childhood cancer [letter]. Lancet 1985; II: 1185.
6. IRCP 1991. Publication 60, vol. 21, no. 1-3. Recommendation of the International Commission on Radiological Protection. Oxford: Pergamon Press; 1991, paragraph 3.4.4.
7. Halnan KE. Radio-iodine treatment of hyperthyroidism - a more liberal policy? Clin Endocrinol Metab 1985; 14: 467-489.
8. Fisher DA. Thyroid function in the fetus and newborn. Med Clin North Am 1975; 59: 1099-1107.
9. Johnson JR. Fetal thyroid dose from intakes of radioiodine by the mother. Health Phys 1982; 43: 573-582.
10. Beebe GW. Epidemiologic studies of thyroid cancer in CIS. In: Karaoglou A. Desmet G, Kelly N, Menzel HG, eds. The radiological consequences of the Chernobyl accident. Brussels: European Commission; 1996:731-740.
11. Akiba S, Lubin J, Ezaki H, et al. Thyroid cancer incidence among atomic bomb survivors, 1958-1979. Radiation Effects Research Foundation 1991: REFR TR 5-91.
12. Ron E, Lubin J, Schneider AB. Thyroid cancer incidence. Nature 1992; 360: 113.
13. Dobyns MB, Hyrmer BA. The surgical management of benign and malignant neoplasms in Marshall Islanders exposed to hydrogen bombs fallout. World J Surg 1992; 16: 126-140.
14. Thomas GA, Williams D, Williams ED. Reversibility of the malignant phenotype in monoclonal tumours in the mouse. Br J Cancer 1991; 63: 213-216.
15. 131I or localized X irradiation to the thyroid and pituitary glands in rats. Radiat Res 1982; 92: 307-319.
16. Walinder G, Sjödén A. Comparison between irradiation of foetuses and adults. Acta Radiol Ther Phys Biol 1973; 12: 201-208.
17. Noteboom JL, Hummel WA, Broerse JJ, et al. Protection of the maternal and fetal thyroid from radioactive contamination by the administration of stable iodide during pregnancy. An experimental evaluation in chimpanzees. Radiat Res 1997; 147: 691-697.
18. 123I-iodide in the thyroid of fetal chimpanzees. Radiat Res 1997; 147: 686-690.
19. 131I in the mouse assessed by the transplacentar micronuclei test. Endocrinologie 1982; 20: 245-248.
20. Cole RJ, Aghamohammadi Z, Cole J, Henderson L. Short-term tests for transplacentally active carcinogens. Multiple-dose regimes in the transplacental micronucleus test. Mutat Res 1982; 105: 115-120.
21. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, 1988.
22. IRCP 1988. Publication 53, vol. 18, no. 1-4. Radiation dose to patients from radiopharmaceuticals. Oxford: Pergamon Press, 1988.
23. 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1975; 17: 146-149.
24. Cox PH, Klijn JG, Pillay M, Bontebal M, Schonfeld DH. Uterine radiation dose from open sources: the potential for underestimation. Eur J Nucl Med 1990; 17: 94-95.
25. Arndt D, Mehnert WH, Franke WG, et al. Radioiodine therapy during an unknown remained pregnancy and radiation exposure of the fetus. A case report. Strahlenther Onkol 1994; 170: 408-414.
26. Palmer AM, Saunders M, James P, Preece AW. Placental transfer and foetal biodistribution. J Nucl Med 1993; 34: 156-157.
27. Palmer AM, Saunders M, James P, Preece AW. Foetal accumulation of radioiodine. Eur J Nucl Med 1994; 21: S37.
28. Berg GEB, Nystrom EH, Jacobsson L, et al. Radioiodine treatment of hyperthyroidism in a pregnant woman. J Nucl Med 1998; 39: 357-361.